Investigating the role of glutaminase in artery damage and disease
Glutaminase in Arterial Injury and Disease
This study is looking at how a specific enzyme called GLS1 affects the growth and movement of cells in our blood vessels, especially after injury or in diseases like diabetes, to help us understand how these changes can lead to problems in our arteries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10856900 on NIH RePORTER |
What this research studies
This research focuses on understanding how the enzyme glutaminase-1 (GLS1) contributes to the formation of lesions in arteries affected by injury and disease. The study examines how GLS1, which processes glutamine into glutamate and ammonia, influences the behavior of vascular smooth muscle cells, particularly their growth and movement. By exploring the effects of GLS1 on these cells, the research aims to uncover potential mechanisms behind arterial remodeling and the impact of conditions like diabetes on vascular health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with atherosclerotic cardiovascular disease or those at risk of arterial injury, particularly patients with diabetes.
Not a fit: Patients without cardiovascular conditions or those who do not have risk factors for arterial injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating arterial diseases, potentially improving cardiovascular health.
How similar studies have performed: Preliminary studies have shown promising results regarding the role of GLS1 in vascular smooth muscle cells, indicating that this approach may yield significant insights into arterial disease.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Durante, William — University of Missouri-Columbia
- Study coordinator: Durante, William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.